What is Centauri Therapeutics?
Centauri Therapeutics is a UK-based biotechnology firm specializing in immunotherapy. The company utilizes its proprietary Alphamer® platform to engineer the immune system, aiming to combat drug-resistant infections and other diseases with high unmet medical needs. This strategic focus positions Centauri Therapeutics at the forefront of developing novel therapeutic solutions in a rapidly evolving healthcare landscape.
How much funding has Centauri Therapeutics raised?
Centauri Therapeutics has raised a total of $43.5M across 4 funding rounds:
Unspecified
$4.3M
Angel/Seed
$1.5M
Series A
$32.6M
Unspecified
$5.1M
Unspecified (2016): $4.3M, investors not publicly disclosed
Angel/Seed (2017): $1.5M, investors not publicly disclosed
Series A (2022): $32.6M supported by Evotec, Boehringer Ingelheim Venture Fund, and REPAIR Impact Fund
Unspecified (2025): $5.1M featuring Carb-X
Key Investors in Centauri Therapeutics
Carb-X
Carb-X is a global initiative focused on accelerating the development of new antibiotics and other life-saving products to combat dangerous drug-resistant bacteria, investing in early-stage antibacterial innovation.
Evotec
Evotec is a global platform company dedicated to discovering and developing highly effective therapeutics, leveraging its data-driven multimodality platform for both proprietary and partnered research.
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund invests in pioneering science and first-in-class therapeutics across various modalities, aiming to redefine care standards and develop new medicines for patients.
What's next for Centauri Therapeutics?
With this significant enterprise-level funding, Centauri Therapeutics is poised for accelerated growth and development. The recent strategic investment will likely fuel further research and clinical trials, expanding the reach of its Alphamer® platform. The company's trajectory suggests a strong emphasis on scaling its operations and advancing its pipeline of innovative treatments, potentially leading to new breakthroughs in infectious disease and beyond.
See full Centauri Therapeutics company page
